A screen to identify drug resistant variants to target-directed anti-cancer agents

This publication has 12 references indexed in Scilit:

• Cell Immortality and Hallmarks of Cancer
  Cell Cycle, 2003
• Issues and progress with protein kinase inhibitors for cancer treatment
  Nature Reviews Drug Discovery, 2003
• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
  New England Journal of Medicine, 2003
• Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
  Cell, 2003
• Novel retroviral vectors to facilitate expression screens in mammalian cells
  Nucleic Acids Research, 2002
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
  Cancer Cell, 2002
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
  Science, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
  Nature Medicine, 1996
• Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
  Proceedings of the National Academy of Sciences, 1988